As Nick Spittal states in this Advarra press release, membership in the Gene Therapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a meaningful credential and important validation that increases sponsors’ confidence in our specialized capabilities to conduct complex clinical research safely.” All Velocity sites are fully prepared … Read more
Congratulations to Henrik Watz, MD, PhD, and our site in Ahrensburg (formerly Velocity Grosshansdorf), Germany, which is currently the top enroller for a global COPD trial! Dr. Watz has just published his 250th full paper, detailing results from the Phase 2 AIRLEAF trial. This study could pave the way for new treatment options in bronchiectasis, … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites business, today announces the appointment of Rachael Buck Ph.D. as Country Head in the U.K. Rachael will lead the five sites Velocity currently owns and operates in the U.K. and will work with the rest of Velocity’s European executive team to expand the company’s footprint in the … Read more
Velocity is proud to be a part of IQVIA’s Prime and Partner Site Programme. IQVIA have created a joint innovation group with representatives from their elite network of Prime and Super Partner sites across Europe, known as the “IQVIA Connected Research Community”. The purpose is to share ideas, lessons-learned, challenges, and innovations across our sites and … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites organization, today announces its further expansion in Europe, adding five sites in Poland after acquiring multi-site network KO-MED Centra Kliniczne and two in Germany, having acquired The Pulmonary Research Institute at the LungenClinic Grosshansdorf and KLB Gesundheitsforschung Lübeck. Velocity’s growth is accelerating across Europe, with 17 locations … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it has expanded into Poland, acquiring its first site, ClinMedica Research. Located in Skierniewice, which is halfway between Warsaw and Lodz, the site marks the first in a series of key acquisitions targeted by the company in Poland by year’s end. In addition to being … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease). According to the NASH education program, … Read more
Shiva Muthiah, Director of UK Operations for Velocity, smiles as she recalls the triumph of a teenage patient battling a painful eczema skin condition. “He used to wear long sleeves and other clothing designed to hide the marks on his skin, but almost immediately after beginning treatment in our clinical trial, the improvement was dramatic … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it is opening greenfield clinical research sites in Bristol, Leicester, and Romford, demonstrating the company’s commitment to the U.K. market. The sites launch at a time when clinical trial activity in the U.K. has fallen in recent years. The number of patients enrolled in commercial … Read more
Even as a teen in Egypt, Amira Nada was drawn to the idea of clinical research and how it could help people live healthier, richer lives. “When I was a young girl, I saw people around me suffering from mental and other health challenges, and I recognized they had unmet needs current treatments couldn’t alleviate,” she … Read more